로딩 중…
StockDiggingStockDigging

KyungdongPharm

011040· KOSDAQ
₩5,060-2.13%
2026-06-19

Price Chart

KyungdongPharm-15.24%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap155.69B KRW
Revenue198.27B KRW
Net Income5.97B KRW
Total Assets309.30B KRW
Net Assets229.60B KRW
Employees383
Value
P/E26.08x
P/B0.68x
PEG0.14x
P/S0.79x
EV/EBITDA47.92x
FCF Yield-0.94%
Profitability
ROE2.60%
ROA1.93%
Op. Margin1.74%
Revenue Growth4.37%
Earnings Growth187.95%
Financial Health
Debt Ratio134.71%
Total Debt25.26B KRW
FCF-1.46B KRW
Cash15.61B KRW
Current Ratio1.63x
Net Debt/EBITDA2.80x
Dividend
Div. Yield5.80%
Div. Growth0.00%
Performance
1Y Return-15.24%
1M Return-4.35%
From 52W High-26.56%
1Y MDD-21.69%
Trading
Volume22,336 shares
Foreign Own.1.81%
Per Share
EPS378 KRW
BPS8,240 KRW

Company Info

CEO 류기성, 김경훈(각자 대표)
Employees 383
Founded 1976
HQ 경기도 화성시, KR

Kyungdong Pharm, established in 1976, manufactures and sells pharmaceuticals, specializing in professional medications like circulatory and digestive system agents, and antihypertensive drugs, including products such as Duoroban Tablets and Alfortin Soft Capsules. The company boasts state-of-the-art solid formulation and injectable manufacturing facilities that meet EU-GMP and US c-GMP standards. Leveraging proprietary raw material synthesis and formulation technologies, it achieves continuous revenue growth through combination drug development, increased investment in biotech firms, and the launch of its WIAVIM health functional food brand.